What made ribose the sugar of choice for life's code? Scientists at Scripps Research may have cracked a major part of this ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

MIT engineers have developed a tiny implantable device that could revolutionize emergency treatment for people with Type 1 ...

Food Structure May Influence Whether You Feel “Full” Yet The physical structure of food can affect the hormones that are released during digestion, suggesting new ways to potentially "hack" our diet.

A new study from Imperial has shown that the physical structure of food influences the hormones released as part of digestion. These hormones include glucagon-like peptide-1 (GLP-1), GIP and PYY ...

Orforglipron is a small-molecule, nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist in clinical development for type 2 diabetes and weight management. Additional data on the efficacy and ...

Glucagon This trend of adding more functions from other hormones to the semaglutide chemical structure is a durable one. Another product, retatrudide, is currently undergoing clinical trials and has ...

In a study published in Cell Research, a research team has, for the first time, resolved the high-resolution in situ structure of the central apparatus (CA) within the axoneme of mammalian sperm.

In the late 2010s, scientists at the Danish drugmaker Novo Nordisk developed a new weekly obesity treatment that targeted three hormones at once. In mice studies, the drug, which activated ...

In mice studies, the drug, which activated receptors of the GLP-1, GIP, and glucagon hormones, caused notable weight loss. But Novo shelved the therapy, STAT reports.

Researchers made small tweaks to the molecular structure of LSD to see if it could be turned into an effective brain-healing treatment.

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight loss treatments.